Showing 5 results for Habibpanah
Peyman Eshghi, Alireza Jenabzadeh, Behnaz Habibpanah,
Volume 6, Issue 3 (Spring 2014)
Abstract
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran.
Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011.
Results: The total recombinant factor VIIa used was 137mg and the total infused platelet concentrates was 68 units, with platelets used in order being: apheresis platelets, leukoreduced pooled platelets, leukoreduced platelets, and random donor platelets with 35, 16, 13 and 4 units respectively. In 90% of bleeding sequences, leukoreduced platelets were available and the average admission per patient was 3.46 times, the average leukoreduced platelets consumption per patient was 4.26 units and the average use of recombinant factor VIIa per patient was 9.13mg. Other Indexes included the average hospitalization per patient per year of 0.69% times, the average consumption of non- random platelet per patient per year of 0.85% units, the average consumption of recombinant factor VIIa per patient per year of 1.83mg, the average consumption of non random platelet for any hemorrhage incidence or elective surgery of 1.3 units, and the average consumption of recombinant factor VIIa for any hemorrhage incidence of 2.8mg.
Conclusion: By extracting the consumption of therapeutical products to treat Glanzmann’s thrombasthenia in our center we could estimate the future treatment needs of our medical center. More thorough investigation of patients from different age groups is recommended to achieve more reliable results.
Key Words: Glanzmann’s thrombasthenia, platelet, rFVIIa, treatment index.
P Eshghi, H Abolghasemi , F Malek , M Naderi , Y Panahi, B Habibpanah, E Fatohlahzadeh, F Gorji,
Volume 7, Issue 4 (Summer 2015)
Abstract
Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 patients with severe hemophilia A were enrolled in this study. Each patient was treated by a 40-50 IU/kg infusion of either plasma derived or recombinant factor VIII after initiation of each of 4 consecutive hemarthrosis episodes in a triple-blind prospective crossover permuted block randomizing method. Clinical efficacy scale score and in vivo recovery of factor VIII was assessed in each of the treated bleeding episodes. Any adverse event was also recorded. Results: The mean±SD level of factor VIII in the plasma versus recombinant groups was 111.5±39 and 115±39, respectively without any significant difference. Response scaling method which assessed pain and range of motion revealed equalized scores along with in vivo recovery, hence treatment success rate was comparable in both groups. One non-recurring, mild skin rash reaction occurred simultaneous with the administration of plasma derived factor. Conclusion: Safacto (r-FVIII) is safe and effective and non-inferior to plasma derived factor VIII in the treatment of hemophilia A related bleeding events.
Behnaz Habibpanah, Zahra Tara, Fatemeh Malek, Rezvan Ardeshiri, Tahmineh Salimi, Belgheis Fasih, Mohammad Reza Managhchi,
Volume 8, Issue 3 (September 2016)
Abstract
Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients’ response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents.
Methods: Hemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients’ preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview.
Results: 80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products.
Conclusion: Our results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential.
Peyman Eshghi, Zahra Khafafpour, Fatemeh Malek, Behnaz Habibpanah,
Volume 11, Issue 4 ( December 2019 2019)
Abstract
Soha Mohammadi Moghaddam, Mitra Khalili, Behnaz Habibpanah,
Volume 13, Issue 4 ( December 2021 2021)
Abstract
Repeated bleeding into the joints often occurs in the first decade of life in patients with hemophilia. Joint degeneration is progressive, and although early treatment can slow the process, destruction of the joint is unavoidable. Hemophilic pseudotumors (HPT) are developed due to recurrent bleeding from extra-articular bone or soft tissues.
